GlassScriptPhysician profile
Robert G Hoehn
NPI 1396751954
$11,521.72
in general payments reported to CMS, 2019-2025
20 companies · $51.62 in 2025
The $51.62 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,932 · 2020: $722 · 2021: $152 · 2022: $50.65 · 2023: $8,297 · 2024: $317 · 2025: $51.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,305 · Travel and Lodging: $939 · Food and Beverage: $838 · Consulting Fee: $360 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,305.00 |
| Travel and Lodging | $939.16 |
| Food and Beverage | $838.18 |
| Consulting Fee | $360.00 |
| Education | $222.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $5,721.70 | 2021-2023 | Qelbree |
| Corium, LLC | $2,581.97 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $763.31 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $468.49 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Allergan, INC. | $422.37 | 2019-2020 | |
| Shire North American Group INC | $414.86 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $224.21 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.87 | 2019-2024 | Trintellix |
| Neos Therapeutics, LP | $116.20 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $110.47 | 2019-2020 | |
| Lundbeck LLC | $104.93 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $94.63 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.11 | 2023-2024 | Caplyta |
| Tris Pharma INC | $83.23 | 2019-2023 | Dyanavel Xr |
| Alfasigma USA, INC. | $37.86 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $35.86 | 2019-2020 | |
| Alkermes, INC. | $33.35 | 2019 | |
| Abbvie INC. | $28.89 | 2021-2025 | |
| Adlon Therapeutics L.P. | $21.43 | 2019 | |
| Amag Pharmaceuticals, INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hoehn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.